



# EMERGENT<sup>®</sup>

We deliver peace of mind  
in an uncertain world

## FACT SHEET

JULY 2024

**10**

Marketed Products

Molecule-to-Market  
**BIOSERVICES**

Development Services  
Drug Substance  
Drug Product  
Packaging

**1.05B**

2023 Total Revenue

**1,300**

Employees



At Emergent, our mission is to **protect and enhance life.**

We develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics. For nearly 25 years, we've been at work defending people from things we hope will never happen—so that we're prepared, just in case they ever do. We do what we do because we see the opportunity to create a better, more secure world. One where preparedness empowers protection from the threats we face. And peace of mind prevails.



### PRODUCT PORTFOLIO<sup>1</sup>

#### GOVERNMENT/MEDICAL COUNTERMEASURES

**BioThrax<sup>®</sup>**

(Anthrax Vaccine Absorbed)

**CYFENDUS<sup>®</sup>**

(Anthrax Vaccine Absorbed, Adjuvanted)

**Anthrasil<sup>®</sup>**

[Anthrax Immune Globulin Intravenous (Human)]

**raxibacumab Injection**

A fully human monoclonal antibody

**ACAM2000<sup>®</sup>**

(Smallpox (Vaccinia) Vaccine, Live)

**VIGIV<sup>®</sup>**

[Vaccinia Immune Globulin Intravenous (Human)]

**BAT<sup>®</sup>**

[Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)]

**Ebanga<sup>™</sup>**

(ansuvimab-zykl)

**TEMBEXA<sup>®</sup>**

(brincidofovir)

#### COMMERCIAL

**NARCAN<sup>®</sup> Nasal Spray**

(Naloxone HCl)



### DEVELOPMENT AND MANUFACTURING EXPERTISE

#### EMERGENT BIOSERVICES

Molecule-to-market services across entire drug development life cycle from clinical through commercial supply

<sup>1</sup> Products approved by U.S. FDA. Ex-US approvals vary by country.



## OUR SCIENCE & DEVELOPMENT PROGRAMS<sup>3, 4</sup>

<b>UniFlu</b> (Universal influenza vaccine)	NIAID VRC	PHASE 1	INFECTIOUS DISEASE
<b>WEVEE VLP</b> (Western, Eastern and Venezuelan equine encephalitic VLP vaccine)	NIAID VRC	PHASE 1	INFECTIOUS DISEASE
<b>Pan-Ebola mAb</b> (Ebola/Sudan monoclonal)	IBT	PRECLINICAL	INFECTIOUS DISEASE

### CORPORATE OFFICE

- Gaithersburg, Maryland

### CORPORATE AFFAIRS

- Washington, DC

### DEVELOPMENT SERVICES

- Gaithersburg, Maryland

### SCIENCE & DEVELOPMENT

- Dublin, Ireland
- Gaithersburg, Maryland
- Winnipeg, Canada

### MANUFACTURING

- Baltimore, Maryland (Camden)
- Canton, Massachusetts
- Lansing, Michigan
- Winnipeg, Canada

### SALES & MARKETING

- Gaithersburg, Maryland
- London, UK
- Philadelphia, Pennsylvania
- Toronto, Canada

### CONTACT INFORMATION

#### Corporate Office

300 Professional Drive  
Gaithersburg, MD 20879 USA  
240.631.3200

#### Investor Inquiries

Richard Lindahl  
EVP and Chief Financial Officer  
240.631.3360  
lindahlr@ebsi.com

#### Bioservices Inquiries

Raj Puri  
VP, Sales and Marketing  
647.286.6039  
purir@ebsi.com

#### Media Inquiries

Assal Hellmer  
Vice President, Communications  
mediarelations@ebsi.com

<sup>3</sup> These product candidates have not been approved by the U.S. FDA or any other regulatory authority.

<sup>4</sup> Status reflects both clinical and nonclinical development under the FDA Animal Efficacy Rule.

IBT - Integrated BioTherapeutics

NIAID - National Institute of Allergy and Infectious Diseases

# EMERGENT<sup>®</sup>

Learn more at

[emergentbiosolutions.com](https://www.emergentbiosolutions.com)



Emergent BioSolutions®, ACAM2000®, Anthrasil®, BAT®, BioThrax®, Cytendus®, RSDL®, NARCAN® NASAL SPRAY, VIGIV®, TEMBEXA® and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. Ebanga™ is a trademark of Ridgeback Biotherapeutics LP. All rights reserved.  
07/30/2023 PP-CORP-ALL-00001

#### Safe Harbor Statement



This document includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, our future goals and growth strategy, total contract value, the timing and results of clinical trials, development-stage programs and regulatory approvals, the intended results of our platforms and technologies, the timing of future deliverables, expansion into new global markets, and any other statements containing the words "will," "believes," "expects," "anticipates," "intends" "plans," "targets," "forecasts," "estimates" and similar expressions. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of publication, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information. There are a number of important factors that could cause the Company's actual results to differ materially from those indicated by such forward-looking statements. Investors should consider this cautionary language as well as the information identified under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports filed with the Securities and Exchange Commission when evaluating our forward-looking statements.